SCHEMBL26412993

SCHEMBL26412993

C=NC(=O)CCCC(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC22A6 Q4U2R8 2/20 0.58
LMNA P02545 4/20 0.50
TSHR P16473 4/20 0.48
NFKB1 P19838 2/20 0.48
PMP22 Q01453 1/20 0.48
CAMK2A Q9UQM7 1/20 0.43
HDAC11 Q96DB2 2/20 0.42
GABRR3 A8MPY1 1/20 0.42
GABRP O00591 1/20 0.42
GABRD O14764 1/20 0.42
HDAC3 O15379 1/20 0.42
GABBR2 O75899 1/20 0.42
CYP1A2 P05177 1/20 0.42
THRB P10828 1/20 0.42
GABRA1 P14867 1/20 0.42
GABRB1 P18505 1/20 0.42
GABRG2 P18507 1/20 0.42
GABRR1 P24046 1/20 0.42
GABRB3 P28472 1/20 0.42
GABRR2 P28476 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20698040 0.92 TSHR (0.60) SLC22A6LMNATSHRNFKB1PMP22
SCHEMBL24012127 0.92 TSHR (0.60) SLC22A6LMNATSHRNFKB1PMP22
SCHEMBL21090066 0.92 TSHR (0.60) SLC22A6LMNATSHRNFKB1PMP22
SCHEMBL26424236 0.79 KMT2A (0.31) SLC22A6LMNAPMP22CYP1A2BLM
Glutarate SCHEMBL1480809 0.76 SLC22A6 (0.85) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL9583826 0.76 SLC22A6 (0.85) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL8855094 0.76 SLC22A6 (0.85) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL8678828 0.76 SLC22A6 (0.85) SLC22A6LMNATSHRNFKB1PMP22
Glutarate SCHEMBL7414 0.76
Glutarate SCHEMBL6701735 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023072971-A2 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2023-05-04 WO disclosed
EP-4170347-A1 GASTRIC INHIBITORY PEPTIDE RECEPTOR LIGANDS 3B Pharmaceuticals GmbH (DE) 2023-04-26 EP disclosed
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 SLC22A6 1827/4885LMNA 201/4885TSHR 684/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.